Prostate-specific membrane antigen positron emission tomography (PSMA-PET) increases detection of regional and distant metastatic prostate cancer (PCa) compared with conventional imaging (eg, computed tomography or bone scan).1-3 Rapid adoption following national approval in 2021 may have initiated a cascade of therapies earlier, and in more patients, than would have occurred with conventional imaging.4 Treatment paradigms for metastatic PCa include intensified regimens with androgen receptor...
